[Adjuvant therapy in uterine myoma].
Many-year studies and clinical experience with steroidal and peptide sexual hormone agonists and antagonists of different generations provides a pathogenetic concept for their use in the treatment of patients with uterine myoma. The impact of adjuvant therapy has been found to be determined by tumor tissue sensitivity to hormonal effects, dosages, therapy duration to a greater extent than the type of a drug from this group. The scope of indications for drug use to suppress the growth of a tumor is limited by its small sizes and its concurrence with benign endometrial hyperplastic processes and/or early internal genital endometriosis.
Vikhliaeva
E M
EM
D000328:Adult; D000367:Age Factors; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003613:Danazol / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005867:Gestrinone / Q000627:therapeutic use; D006801:Humans; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery
D004965:Estrogen Antagonists; D045167:Progesterone Congeners; D005867:Gestrinone; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003613:Danazol